Trial Profile

A phase II, randomized, controlled, open-label study to evaluate the efficacy and safety of Pegylated IFN alfa-2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary)
Indications COVID 2019 infections
Focus Proof of concept; Therapeutic Use
Sponsors Cadila Healthcare; Zydus Cadila

Most Recent Events

05 Apr 2021 According to a Zydus Cadila media release, results from this trial were published in the International Journal of Infectious Diseases.
01 Apr 2021 Primary endpoint (improvement in clinical status on day 15, measured by the WHO 7-point ordinal scale) has been met as per results published in the International Journal of Infectious Diseases
01 Apr 2021 Results published in the International Journal of Infectious Diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com